STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report

STK3-ALK, a Novel ALK Rearrangement in Non-Small Cell Lung Cancer With Sensitivity to Tyrosine Kinase Inhibitors: A Case Report

Anaplastic lymphoma kinase (ALK) rearrangement occurs in 5% to 8% of patients with non-small cell lung cancer (NSCLC). More than 90 different ALK fusion partners have been discovered in NSCLC patients, and ALK tyrosine kinase inhibitors (TKIs) such as crizotinib and alectinib have achieved tumor res...

Full description

Bibliographic Details
Main Authors: Chunlai Feng, Rong Zhou, Feng Liu, Tingting Wang, Sisi Liu, Yang Shao
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-08-01
Series:Frontiers in Oncology
Subjects:
ALK rearrangement
NSCLC
STK3-ALK
brain metastases
TKI
case report
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.700341/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.700341/full

Similar Items